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Abstract
Background: Bisacodyl is a member of the diphenylmethane family and is considered 
to be a stimulant laxative. It has a dual prokinetic and secretory action and needs 
to be converted into the active metabolite bis- (p- hydroxyphenyl)- pyridyl- 2- methane 
(BHPM) in the gut to achieve the desired laxative effect. Bisacodyl acts locally in the 
large bowel by directly enhancing the motility, reducing transit time, and increasing 
the	water	content	of	the	stool.	A	recent	network	meta-	analysis	concluded	that	bisa-
codyl showed similar efficacy to prucalopride, lubiprostone, linaclotide, tegaserod, 
velusetrag,	elobixibat,	and	sodium	picosulfate	for	 the	primary	endpoint	of	≥3	com-
plete	 spontaneous	bowel	movements	 (CSBM)/week	 and	 an	 increase	of	 ≥1	CSBM/
week over baseline. The meta- analysis also found that bisacodyl may be superior to 
the other laxatives for the secondary endpoint of change from baseline in the number 
of spontaneous bowel movements per week in patients with chronic constipation. 
This observation stimulated the authors to review the available literature on bisaco-
dyl, which has been available on the market since the 1950 s.
Purpose: The aim of the current review was to provide an overview of the historic 
background,	structure,	function,	and	mechanism	of	action	of	bisacodyl.	Additionally,	
we discuss the important features and studies for bisacodyl to understand its peculiar 
characteristics and guide its use in clinical practice, but also stimulate research on 
open questions.
K E Y W O R D S
Bisacodyl, constipation, laxative, mode of action, secretagogue, sodium picosulfate
Key Points
• Bisacodyl is a locally acting laxative with unique dual mechanism of action upon gut secretion 
and motility, and is considered a standard treatment for constipation.
• We provide the first overview of the historic background, pharmacokinetics, and mechanism 
of action of bisacodyl, including practical guidance for clinicians and explore open questions 
warranting further research.
• Recent advances in the understanding of colonic motility and the distinct effects of available 
laxatives on colonic motor patterns suggest that bisacodyl still has unexplored potential.
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1  |  INTRODUC TION
Constipation is one of the most prevalent gastrointestinal conditions 
presenting to primary care or subspecialty physicians and surgeons 
globally. In a systematic review and meta- analysis of 41 adult popu-
lations in 2011, Ford et al estimated the pooled global prevalence of 
constipation to be 14%, with a similar prevalence observed in most 
geographical regions.1 Constipation represents a significant cost 
for the healthcare system worldwide.2- 4 Indeed, recent Hospital 
Episode Statistics data collected between 2017 and 2018 in the UK 
documented that 71,430 people in England were admitted to hos-
pital with constipation; this is equivalent to 196 people a day, and 
£162 million was spent by NHS England on treating the condition 
during this period.5
Constipation is characterized by a number of symptoms, such as 
hard stools, excessive straining, infrequent bowel movements, and/
or a feeling of incomplete evacuation.1,6 It can occur on an occa-
sional/episodic basis, which is often treated by self- medication, or 
a chronic basis (typically >4 weeks or in accordance with consensus 
criteria >3 months),2,6,7 which is likely to be treated by a physician or 
through specialty care.
Constipation is categorized into idiopathic chronic constipation 
(CC) and constipation secondary to organic diseases (such as neu-
rological disease) or to certain treatments (such as opioids).6 The 
causes of CC are still unclear, but alteration of colonic and anorec-
tal motility have been implicated in the pathophysiology of symp-
toms.6,8 Patients are generally classified into three groups, based 
on assessments of colonic transit and anorectal function: normal 
transit constipation, slow transit constipation (STC), and pelvic floor 
dysfunction or defecation disorders.6,9 The contribution of abnor-
malities in colonic secretion and absorption to the pathophysiology 
of constipation is poorly understood. Several drugs which increase 
colonic secretion are used to manage constipation.6,10 In the colon, 
high	amplitude	propagated	contractions	(HAPCs)	play	a	relevant	role	
in propulsion,6 and they occur mostly at awakening and after meals.11 
Studies have shown decreased or absent colonic motor response 
and	lower	incidence	of	HAPCs	in	patients	with	STC,	compared	with	
healthy volunteers, as investigated by the use of conventional co-
lonic manometry.8,12- 14
A	range	of	pharmacological	treatments	for	constipation	exist	and	
those with demonstrated efficacy compared with placebo include 
osmotic (polyethylene glycol [PEG]) or stimulant laxatives (bisaco-
dyl and sodium picosulfate), prokinetics (prucalopride), and secret-
agogues (linaclotide and plecanatide).6 In a recent systematic review 
and network meta- analysis, bisacodyl, sodium picosulfate, prucalo-
pride, and velusetrag were shown to be more effective than placebo 
in	a	responder	analysis	comprising	≥3	complete	spontaneous	bowel	
movements	 (CSBM)	per	week	and	an	 increase	over	baseline	of	≥1	
CSBM per week.15 Interestingly, the analysis also suggested that bi-
sacodyl may be superior to prucalopride, lubiprostone, linaclotide, 
tegaserod, velusetrag, elobixibat, and sodium picosulfate for change 
from baseline in the number of spontaneous bowel movements per 
week in patients with CC.15 This observation, in combination with 
the fact that bisacodyl is also commonly used as a rescue medication 
in clinical trials designed to study the efficacy of new constipation 
compounds,16- 20 suggested to the authors of the present review that 
a deep understanding of bisacodyl would be useful.
2  |  HISTORIC BACKGROUND OF 
BISACODYL
Bisacodyl is a locally acting laxative and has been used to treat 
constipation and facilitate defecation since the 1950 s.15,21,22 
Bisacodyl is part of the diphenyl methane derivatives group.23,24 
Phenolphthalein, one of the earliest members of this derivatives 
group, had a weak laxative efficacy and required 30- 200 mg daily 
to elicit a response in adults.25 Subsequent systematic structure- 
activity studies of compounds structurally related to phenolphtha-
lein revealed the diphenolic laxative group.26,27
2.1  |  Structure- activity insights
The term diphenolic laxatives are derived from the two free hydroxyl 
groups in para positions on the two benzene rings, which are neces-
sary to provoke a secretagogue and laxative action.28	Additionally,	
the secretagogue efficacy depends on the structure of the third aryl 
group. If a nitrogen is present in the aromatic ring, the distance from 
the central carbon atom of the methyl group and the dissociation 
constant of the nitrogen group will affect the secretagogue action.28
Bisacodyl and sodium picosulfate are both prodrugs7 and 
are converted in the gut into the same active metabolite, bis- (p- 
hydroxyphenyl)- pyridyl- 2- methane (BHPM), which causes the 
desired laxative effect.29 Conversion of bisacodyl into BHPM is 
mediated by the action of endogenous deacetylase enzymes on the 
mucosa of the small intestine and colon, whereas sodium picosulfate 
is converted to BHPM by the action of colonic bacteria desulfate 
enzymes (eg, arylsulfate sulfotransferase of Eubacterium rectale) 
(Figure 1).30	 As	 sodium	 picosulfate	 depends	 on	 bacterial	 activity,	
the use of antibiotics can affect its activity.29 Similar considerations 
are valid for senna and cascara, which are also metabolized by colon 
bacteria.31
3  |  PHARMACOKINETIC S
Bisacodyl is administered as a 5- layer enteric- coated tablet (Figure 2) 
that does not disintegrate until it reaches the lower intestine, thereby 
reducing the already limited absorption and ensuring it is converted 
into BHPM in the colon.7,24 Bisacodyl is available for adults and ado-
lescents (age over 10 years) as an enteric- coated oral dragee/tablet 
at a dose of 5 mg or as a rectal suppository at a dose of 10 mg,13,32,33 
and for children aged 4– 10 years as an oral tablet or rectal supposi-
tory at a dose of 5 mg.32,34 The onset of action occurs between 6 
and 12 hours after oral administration, while the suppository can 
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take effect between 15 and 60 minutes following rectal adminis-
tration.32,33 Tablets are recommended to be taken at night and the 
bowel movement typically occurs the following morning, at the time 
when colonic motor activity is normally highest.11,32
After	oral	and	rectal	administration,	only	small	amounts	of	the	
drug are absorbed and are almost completely conjugated in the in-
testinal wall and the liver to form the inactive BHPM glucuronide.32 
There is no detectable free BHPM in the plasma, even following mul-
tiple once- daily dosing with 2 x 5 mg bisacodyl enteric- coated tab-
lets, although the inactive glucuronidated BHPM is detectable.7,35 
The mean plasma elimination half- life of BHPM has been estimated 
to be 7.7 hours for bisacodyl tablets.7 Following the administration 
of enteric- coated bisacodyl tablets, an average of 51.8% of the dose 
was recovered in the feces as free BHPM and 10.5% of the dose 
was recovered in the urine as BHPM glucuronide.29 In a study by 
Friedrich et al, 12% of the bisacodyl dose was recovered as total 
(free +glucuronidated) BHPM in the urine.7 In the latter study, the 
authors also investigated excretion of total and free BHPM into 
human breast milk in two groups of eight healthy lactating women 
and found that it did not accumulate after multiple administrations 
of bisacodyl and was not excreted into the breast milk.7 No data 
from controlled human pregnancy studies are available. Long- term 
post- marketing surveillance has not shown evidence of undesirable 
or damaging effects during pregnancy. Early studies reported mild 
side effects 36- 38 and other reviews39- 42 deem bisacodyl safe for use 
during pregnancy. For the suppositories, a prior study demonstrated 
that in half (n = 6/12) of the healthy volunteers included, no plasma 
levels of bisacodyl metabolites could be detected and only 3.1% of 
the dose was excreted in the urine.35
Bisacodyl is a locally acting laxative and absorption is not re-
quired for the laxative effect. The time to onset depends on the time 
taken for the prodrug to reach the lower intestine and be converted 
in the active pharmaceutical ingredient BHPM.35 There is a lag time 
before any increase in plasma levels of glucuronidated BHPM is seen. 
The absence of a temporal relationship between the laxative effects 
and the plasma levels supports the view that BHPM acts locally.35
4  |  MECHANISM OF AC TION OF 
BISACODYL
An	overview	of	the	key	results	from	 in vitro and in vivo studies in-
vestigating the mechanism of action of bisacodyl is provided in 
Table 1, with information regarding the animal model used (where 
applicable).
Animal	studies	to	date	have	investigated	the	effect	of	bisacodyl	
on motility and water transport. In 1975, Schubert et al investigated 
the effect of bisacodyl in isolated smooth muscle from the large and 
small intestine of guinea pigs.43 Bisacodyl was found to increase the 
contraction in the isolated muscle, with a dose- dependent response 
that was greater in the large than in the small intestine.43 In 1977, 
Saunders et al investigated the effect of bisacodyl in vitro from rat 
intestinal segments and found it inhibited net water transport, with 
the degree of inhibition linearly related to the logarithmic intralu-
minal concentration of bisacodyl.44	A	more	recent	study	in	rats	in-
vestigated	the	role	of	aquaporin	3	(AQP3),	which	is	thought	to	play	
a role in water transfer in the colon, and found that after oral ad-
ministration of bisacodyl, expression of prostaglandin E2 increased 
significantly	whereas	AQP3	 levels	decreased	by	up	 to	60%.45 The 
reduced	expression	of	AQP3	inhibits	water	transfer	from	the	luminal	
to vascular side of the colon and leads to a laxative effect, that is 
thought to be induced by increased secretion of prostaglandin E2. 
However,	 although	 AQP3	 is	 expressed	 in	 mucosal	 epithelial	 cells	
in the human colon,46 the physiological role and the regulation of 
AQP3	expression	in	humans	are	little	known.47 Interestingly, in this 
manuscript the authors suggested that concomitant administration 
of nonsteroidal anti- inflammatory drugs could reduce the effect of 
bisacodyl.45
The effects of bisacodyl on colon motility have been confirmed 
in vitro	in	humans.	An	early	study	demonstrated	that	high	concentra-
tions of bisacodyl (10 μg/mL, corresponding to 36 μM/L) enhanced 
contractility in muscle strips of human large intestine through a 
tetrodotoxin- insensitive mechanism.48 In 2000, Voderholzer et al in-
vestigated the effect of BHPM on human colon motility in isolated 
F I G U R E  1 Metabolism	of	bisacodyl	and	sodium	picosulfate	into	
BHPM. BHPM, bis- (p- hydroxyphenyl)- pyridyl- 2- methane.
F I G U R E  2 Structure	of	the	bisacodyl	dragee.
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TA B L E  1 Overview	of	the	key	studies	investigating	the	mechanism	of	action	of	bisacodyl.
Study Model Key results
In vitro
Schubert, et al.43 Guinea pig Bisacodyl (60 µg/mL) initiated dose- dependent contractile responses in isolated guinea pig 
longitudinal muscle fibers (guinea pig isolated ileum and taenia coli)
Saunders, et al.44 Rat Bisacodyl (0.05– 2.0 mg/100 mL) inhibited net water transport from the lumen of the small 
intestine and colon in rats. Inhibition of net water transport in rat intestine was negatively 
correlated to the dose of bisacodyl
Saunders, et al,44 Human Bisacodyl (1.0 mg/100 mL) inhibited net water transport from the lumen of the small intestine in 
humans
Mitznegg, et al,48 Human Maximal contractions in isolated muscle strips of human colon after treatment with bisacodyl 
(10 µg/mL) were delayed in onset compared with those achieved with acetylcholine (1 µg/
mL), histamine (1 µg/mL), and nicotine (0.5 µg/mL)
Voderholzer, et al.49 Human BHPM dose- dependently induced contractions in isolated human colon that were not inhibited 
by atropine, tetrodotoxin, or Nω- Nitro- L- arginine. In the presence of BHPM, dose- response 
curves of carbachol and substance P were shifted to the right, showing an inhibitory effect. 
The inhibitory effect occurred at high concentrations of BHPM
Krueger, et al.50 Human BHPM (0.5– 5 µM) increased tone in muscle from the large and small intestine in a 
concentration- dependent manner with greater effect on large intestine and on longitudinal 
as compared with circular smooth muscle.
In vivo
Ikarashi, et al.45 Rata  Fecal water content increased significantly from baseline at 2 hours after oral bisacodyl (20 mg/
kg)	administration.	Aquaporin	3	levels	in	the	colon	decreased	significantly	from	baseline	at	2	
hours after bisacodyl administration
Ewe, et al.57 Human Healthy 
volunteers
Following the administration of bisacodyl (5.5– 6.6 mg) by intestinal perfusion into the cecum, 
sodium and water absorption was reversed, with sodium and water entering the intestinal 
lumen and an increase in potassium secretion.
Ewe56 Healthy volunteers Bisacodyl (10 mg/10 mL ethanol/1L via intestinal perfusion) induced reversible net secretion of 
water and sodium.
Giorgio, et al.67 Human (Pediatric 
patients)
In colonic segments after intracolonic infusions of bisacodyl (0.2 mg/kg and 0.4 mg/kg), the 
number	of	HAPCs	was	decreased	and	low-	amplitude	propagating	sequences	were	more	
frequent in STC patients than in control subjects
Saunders, et al.44 Human (Patients with 
ileostomies)
Bisacodyl (5 mg) administered orally every 6 hours to five patients with ileostomies increased 
stoma output by 15%
Gosselink, et al.55 Human (Women 
with obstructed 
defecation)
Intrarectal bisacodyl (10 mg) significantly increased rectal tone from baseline in women with 
obstructed defecation and in controls. Tonic response was absent or significantly impaired in 
patients with prolonged colonic transit time
De Schryver, et al.13 Human (Patients with 
STC and healthy 
volunteers)
In patients with STC, there was decreased colonic motor response to a meal and to intracolonic 
bisacodyl (3 mg/10 mL 0.9% saline) versus healthy volunteers. Mean amplitude and 
frequency	of	HAPCs	were	decreased	and	time	to	onset	of	HAPC	was	prolonged	in	patients	
with STC versus healthy volunteers
Herve, et al.14 Human (Patients with 




constipation and promoted propagated motor activity in the majority of patients compared 
with versus healthy volunteers
Corsetti, et al.82 Human (Patients with 
STC and healthy 
volunteers)
Pan- colonic pressurizations (simultaneous pressure increases) and associated relaxations of the 
anal sphincter represented a new colonic motor pattern appearing to be defective in patients 
with STC who did not respond to pharmacological treatment with intracolonic bisacodyl





Manabe, et al.53 Healthy volunteers Administration	of	oral	bisacodyl	(5	mg)	resulted	in	accelerated	emptying	of	the	ascending	colon	
relative to placebo





aRats were euthanized and tissue obtained for testing at various timepoints after administration of bisacodyl. 
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smooth muscle strips and found that bisacodyl has a stimulatory 
effect on the human colon, which could be inhibited by calcium 
channel blockers, and appears not to be present at high concentra-
tions of BHPM.49 More recent data from an in vitro study in humans 
confirmed the dual effect of bisacodyl on motility and secretion. In 
a study by Krueger et al, BHPM (administered at a maximum dose 
of 5 µM, estimated to be in accordance with the concentration of 
BHPM produced following administration of 10 mg of bisacodyl) en-
hanced colon mucosal secretion, and small bowel and colon muscle 
tone.50 The increase in muscle tone was through direct myogenic 
action involving L- type calcium channels and was larger in longitu-
dinal than circular muscle, and in the large than the small intestine. 
The effect was sustained for up to 3.5 hours, which was the lon-
gest recording period.50 Two mechanisms were involved in BHPM- 
induced ion secretion into the lumen: potassium secretion when 
BHPM acts from the luminal site and nerve- mediated chloride and 
bicarbonate secretion once BHPM is absorbed.50 Under these ex-
perimental conditions, both pro- secretory actions lasted between 
20 and 30 minutes.
Most in vivo studies in humans have focused on the effect of 
bisacodyl on colon motility after direct intraluminal application. This 
test has been, and continues to be, used in clinical practice to ex-
clude colonic inertia (absence of colon motor response to meal and 
stimulant drug) in patients with STC refractory to pharmacological 
treatments.51,52 In general, these studies showed that intraluminal 
administration	of	bisacodyl	induced	HAPCs	both	in	healthy	subjects	
and in most of the patients with constipation (see Table 1 for key 
results from relevant in vivo studies). Similar findings for the effects 
of bisacodyl on colonic motility have been observed in pediatric pa-
tients (see Table 1 for key results from relevant in vivo studies).
Few studies have evaluated the effect of oral administration of 
bisacodyl on motility in healthy human volunteers. In 2009, Manabe 
et al evaluated the effect of oral bisacodyl on gut transit in 25 healthy 
volunteers.53 The authors found that bisacodyl 5 mg accelerated 
the emptying of the ascending colon compared with placebo, with 
a median time of 6.5 hours and 11.0 hours, respectively.53 More re-
cently, Corsetti et al assessed colonic motility with oral PEG 13.8 g, 
bisacodyl 10 mg, prucalopride 2 mg, and placebo in 10 healthy vol-
unteers using high- resolution manometry.54	Administration	of	PEG	
resulted in a significant increase in the number of long- distance low- 
amplitude propagating contractions vs. placebo, whereas bisacodyl 
significantly	 increased	the	number	of	HAPCs	versus	PEG,	prucalo-
pride,	and	placebo.	Prucalopride	increased	the	amplitude	of	HAPCs	
and appeared to increase the number of simultaneous pressure in-
creases.54 Similarly, there have only been a few mechanistic studies 
investigating the effect of bisacodyl suppositories. In a study involv-
ing women with obstructed defecation, rectal tone was measured 
before and after administration of a rectal suppository of bisacodyl 
10 mg.55 Rectal tone increased significantly after topical application 
in both patients with normal colonic transit time and control sub-
jects. In patients with a prolonged colonic transit time, this response 
was absent or significantly reduced, and in all patients (normal and 
prolonged transit time) the rectal sensory perception (evoked urge 
to defecate) was impaired.55
Before the recent in vitro study by Krueger et al (the results of 
which are discussed earlier), the effect of bisacodyl on gut secretion 
was investigated in vivo in humans. In 1987, Ewe studied the effect 
of intestinal perfusion of bisacodyl (10 mg in 10 mL ethanol and 1 L 
perfusate) on the transport of intestinal electrolytes, glucose, and 
water in six healthy volunteers.56 Bisacodyl induced reversible net 
secretion of sodium and water, and enhanced potassium secretion.56 
Mean transit time was also reduced, while mean flow rate increased, 
corresponding to the net change from absorption to secretion of 
water. The author concluded that the secretory effect of bisacodyl 
was mainly responsible for the decreased transit times and it was 
assumed that this effect was mainly caused by enhanced fluid flux 
into the lumen.56 These findings on the secretory effects of bisac-
odyl were supported by earlier findings by Ewe et al, who perfused 
a colonic segment in five healthy volunteers through a modified 
4- luminal perfusion tube.57 In order to assess the effect of bisacodyl 
on water and electrolyte transport, volunteers were perfused with 
standard	 solution	 before	 and	 after	 delivery	 of	 bisacodyl.	 At	 each	
stage of the experiment, the rectal flow was collected through an 
anal catheter for analysis of volume and electrolyte concentration. It 
was demonstrated that, compared with standard solution, perfusion 
with 5.5- 6.6 mg of bisacodyl reversed sodium and water absorption 
and increased potassium secretion.57
5  |  THER APEUTIC EFFIC ACY AND SAFET Y 
DATA FROM CLINIC AL TRIAL S
Clinical investigations and studies on bisacodyl and sodium picosul-
fate have been performed since the 1950 s according to standards 
applicable at the time they were conducted. Since the introduction 
of good clinical practice, major clinical trials have been performed by 
Kienzle- Horn et al (2006)22 and Kamm et al (2011)21 for bisacodyl, 
and Mueller- Lissner et al (2010)58 for sodium picosulfate. Kienzle- 
Horn (2007)59 also conducted a comparative study of bisacodyl and 
sodium	picosulfate.	An	overview	of	the	clinical	trials	of	bisacodyl	and	
sodium picosulfate is provided in Table 2. Large, randomized con-
trolled trials for other stimulant laxatives like senna are missing from 
the literature. In 2006, Kienzle- Horn et al reported the results of 
a double- blind, randomized, placebo- controlled study that investi-
gated the effect of bisacodyl 10 mg daily for 3 days on the frequency 
and consistency of stools in 55 patients with CC.24 Bisacodyl was 
associated with a significantly greater mean number of stools per 
day compared with placebo, as well as an improvement in mean stool 
consistency score. Treatment was well tolerated, with a similar in-
cidence	of	adverse	events	(AEs)	between	bisacodyl	and	placebo.24
It was not until 2011 that Kamm et al reported the results of the 
first large randomized, double- blind, placebo- controlled, parallel- 
group study that determined the efficacy and safety of treatment 
with bisacodyl in patients with constipation (as defined by the Rome 
III criteria) over a 4 week period.21 Patients were randomized 2:1 
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to receive either bisacodyl 10 mg once daily (n = 247) or matching 
placebo (n = 121). Patients receiving bisacodyl had a significantly 
increased mean number of CSBMs per week over the treatment 
period, from 1.1 at baseline for both groups to 5.2 with bisacodyl 
and	1.9	 in	the	placebo.	 (Figure	3A).21 In addition to improvements 
in objective constipation- related symptoms, such as straining with 
defecation or stool consistency, patients also reported improve-
ments in other parameters.21 Overall satisfaction scores for bowel 
habits, bothersomeness of constipation, and abdominal discom-
fort and bloating improved with bisacodyl compared with placebo 
(unpublished data, see Table 2). Over the study period, the most 
common	AEs	 in	patients	treated	with	bisacodyl	were	diarrhea	and	
abdominal pain, experienced by 53.4% and 24.7% of patients, re-
spectively, compared with 1.7% and 2.5% in the placebo group, 
respectively. 17.8% of the bisacodyl- treated patients withdrew pre-
maturely	because	of	AEs,	compared	with	only	5.0%	of	the	placebo	
group. In the bisacodyl group, the percentage of premature with-
drawals decreased over time from 10.5% at week 1 to 2.5% at week 
4. However, it should be noted that patients started treatment with 
a bisacodyl dose of 10 mg daily and were allowed to reduce their 
dose during the treatment period. The percentage of patients with 
drug-	related	AEs	in	the	bisacodyl	group	declined	markedly	from	57%	
at Week 1 to 5% at Week 4 (Table 3 and Figure 3B). This reduction 
in	AEs	corresponds	with	the	reduction	of	the	bisacodyl	dose	during	
the treatment period. Patients reduced their mean weekly dose from 
56 mg in Week 1 to 48 mg in Week 2 and 45 mg in Week 4, with 
58% of patients in the bisacodyl arm able to reduce their daily dose 
from 10 mg to 5 mg by the end of the treatment period (Figure 3C).21 
This finding suggests that the starting dose of bisacodyl selected in 
this study was too high for a considerable proportion of patients and 
that treatment was well tolerated once a patient identified a suitable 
dose. Indeed, treatment tolerability assessed by the patient (using a 
4- point ordinal verbal rating scale: 1=good, 4=bad) was significantly 
better in the bisacodyl group compared with placebo.21
In 2010, Mueller- Lissner et al reported the results of a random-
ized, double- blind, placebo- controlled, parallel- group study that 
investigated the safety and efficacy of sodium picosulfate over 
4 weeks in 367 patients with constipation (as defined by the Rome 
III criteria).58 Patients were randomized 2:1 to receive either sodium 
picosulfate drops (10 mg) or matching placebo. The mean number of 
CSBMs significantly increased from 0.9 to 3.4 in the sodium picosul-
fate group, compared with an increase from 1.1 to 1.7 in the placebo 
group.58 Significant improvements in health- related quality- of- life, 
as	 measured	 by	 the	 constipation-	related	 Patient	 Assessment	 of	
Constipation Quality- of- Life questionnaire, were observed in the so-
dium picosulfate group compared with the placebo group. Symptoms 
and satisfaction with bowel habit were also improved following so-
dium picosulfate compared with placebo.58	The	most	common	AE	was	
diarrhea, reported in 74 (31.8%) patients in the sodium picosulfate 
group	and	six	(4.5%)	patients	in	the	placebo	group.	Abdominal	pain	
was reported in 13 (5.6%) and three (2.2%) patients in the sodium pi-
cosulfate and placebo groups, respectively.58 In the group of patients 
F I G U R E  3 Efficacy	and	safety	data	per	week	over	the	4	week	
treatment	period.	(A)	Change	in	bowel	movement	frequency,	
(B)	Percentage	of	patients	experiencing	AEs,	(C)	Percentage	of	
patients taking 1 or 2 tablets bisacodyl or placebo. Patients can 
self- manage their stimulant laxative dose to achieve effective 
relief of chronic constipation, as demonstrated in two randomized 
trials. Poster number S1328 presented at Digestive Disease Week 
2010, republished with permission from Clinical Gastroenterology 
and Hepatology and the authors, respectively.81	AE,	adverse	
event; CSBM, complete spontaneous bowel movement; SBM, 
spontaneous bowel movement. Data from Kamm et al.,201121 and 
Mueller- Lissner et al., 201881
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treated with sodium picosulfate, 5.2% of the patients discontinued 
the study prematurely, whereas the percentage in the placebo group 
was 3.8%. In the SPS group, the percentage of premature withdraw-
als was 0.4% during weeks 1 and 4. The highest percentage of 3.1% 
premature withdrawals have been reported during week 2. Over the 
course	of	the	study,	the	number	of	drug-	related	AEs	decreased	sig-
nificantly after the first week. Similar to the Kamm et al study with 
bisacodyl,21	this	reduction	in	drug-	related	AEs	was	in	parallel	with	the	
individual adjustment of the dose of sodium picosulfate.58
Kienzle- Horn et al conducted a randomized, open- label, parallel- 
group comparison of the safety and efficacy of bisacodyl and so-
dium picosulfate (both 5– 10 mg daily) over a 4- week period in 144 
patients with CC.59 Both treatments were equally effective in treat-
ing CC, with significant improvements in symptoms seen in both 
groups. Neither treatment significantly affected serum electrolytes 
(Figure 4).59
In light of the limited head- to- head randomized controlled trials 
of treatments for CC, the clinically relevant efficacy and safety find-
ings discussed above have been examined in systematic reviews and 
meta- analyses by Ford et al,60 Nelson et al,15 and Luthra et al.61 Ford 
et al noted that the mean number of stools per week was signifi-
cantly increased for both osmotic and stimulant laxatives compared 
with placebo in patients with CC.60 Nelson et al observed similar 
efficacy between bisacodyl, prucalopride, lubiprostone, linaclotide, 
tegaserod, velusetrag, elobixibat, and sodium picosulfate for the pri-
mary	endpoints	of	≥3	CSBMs/week	and	an	increase	from	baseline	by	
≥1	CSBM/week.15 However, the authors concluded that bisacodyl 
may be superior in the secondary endpoint of change from baseline 
of SBMs per week.15 Similar conclusions were reached in a recently 
published network meta- analysis by Luthra et al,61 in which bisaco-
dyl and sodium picosulfate were ranked first at 4 weeks based on an 
endpoint	of	failure	to	achieve	≥3	CSBMs	per	week.	The	authors	also	
reported that bisacodyl was ranked last in terms of safety for total 
number	of	AEs	and	abdominal	pain	when	assessing	 the	 treatment	
period as a whole.61	 The	 reduction	of	AEs	over	 time	with	bisaco-
dyl occurred in parallel with the reduction of the dosage during the 
treatment	period.	While	AEs	are	known	to	decrease	in	such	studies	
over time in the absence of dose change, it seems reasonable to sug-
gest that clinicians could consider starting with a lower dosage and 
increase in case of need.
Additionally,	the	fear	of	causing	electrolyte	imbalance	has	been	
disputed in multiple studies which confirmed that the use of bisac-
odyl does not lead to clinically relevant electrolyte loss.21,58,59,62,63
6  |  WHAT C AN THESE DATA TELL US 
ABOUT BISACODYL?
6.1  |  What are the key aspects of bisacodyl 
pharmacology that clinicians should remember?
Bisacodyl is a prodrug metabolized in the intestinal mucosa and not 
by bacteria, such as with other stimulant laxatives like picosulfate, 
senna, and cascara. This suggests that a more consistent effect of 
bisacodyl is possible, with less influence from factors affecting gut 
microbiota. Bisacodyl is available as oral (5- layer enteric- coated 
tablets) and rectal (suppository) formulations, permitting a variable 
TA B L E  3 Overall	summary	of	adverse	events	by	week	for	
patients with investigator- defined drug- related adverse events in 
the Kamm et al. 2011 bisacodyl study 21
Timepoint
Placebo Bisacodyl








Week 1 117 (100) 6 (5.1) 239 (100) 136 
(56.9)
Week 2 114 (100) 2 (1.8) 216 (100) 14 (6.5)
Week 3 111 (100) 1 (0.9) 204 (100) 11 (5.4)
Week 4 105 (100) 0 (0.0) 192 (100) 9 (4.7)
F I G U R E  4 Serum	levels	of	sodium	
and potassium at the beginning and end 
of treatment with bisacodyl, sodium 
picosulfate, and placebo, respectively, 
for	4	weeks	(mean	±SD).	SPS,	sodium	
picosulfate; Republished with 
permission, from Mueller- Lissner, Open J 
Gastroenterology, 2013.
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immediacy of effect; bowel movement occurs in approximately 
6– 12 hours following administration with oral tablets and approxi-
mately 20 minutes with the suppository (in some cases an effect oc-
curred 45 minutes after administration). The available oral dosing for 
adults is 5– 10 mg once daily. On the basis of randomised controlled 
trial findings,21 5 mg seem to be better tolerated. Therefore, it is sen-
sible to recommend treatment initiation with 5 mg and subsequent 
dose adjustment on an individualised basis. However, as studies with 
formal fixeddosed comparison of the 5 and 10 mg dosages are not 
available, such a comparison may provide additional information on 
efficacy and tolerability of the two- dose strength.21	Available	dos-
ing in the rectal form is 10 mg for adults, adolescents, and children 
above 10 years of age,32,64 and 5 mg for children aged 4– 10 years.34 
With both formulations, the active metabolite of bisacodyl has no 
relevant systemic absorption.21,29,53,65
6.2  |  What are the key aspects of the 
mechanism of action of bisacodyl?
Bisacodyl has a dual prokinetic and secretory action directly enhanc-
ing colon motility, reducing transit time, and increasing the water 
content of the stool (Figure 5). Colonic motility can present either 
as phasic contractions (contractions of short duration), or tone (pro-
longed state of contractions).66 Local administration in vitro48- 50 and 
rectal administration of suppositories in vivo55 have been shown to 
increase smooth muscle tone in healthy volunteers and patients with 
obstructed defecation and normal colonic transit. In vitro, this effect 
on gut tone seems to be more pronounced on the longitudinal than 
the circular smooth muscle, and in the colon than in the ileum, and 
persists for up to 3.5 hours.50
Intraluminal administration of bisacodyl in the colon and/or in 
the	rectum	trigger	phasic	HAPCs	within	60	minutes.55,67 These con-
tractions start in the proximal colon and propagate distally in both 
healthy and constipated adults, and in children without colonic iner-
tia.6	In	addition,	these	HAPCs	are	similar	to	those	occurring	physiolog-
ically.13,14,68,69 It is currently unclear whether the stimulation of these 
HAPCs	 in vivo in humans is related to the activation of a neuromus-
cular pathway intrinsic and/or extrinsic to the gut wall, requires the 
concomitant presence of gut distension, and/or is determined by the 
activation of only the longitudinal smooth muscle layer or also circular 
muscle.50
6.3  |  Can the above information guide the 




orally or locally in different formulations would be beneficial in order 
to clarify whether this can be used in clinical practice in different 
subgroups of patients. It is possible that patients presenting with 
defecation disorders and normal colonic transit might benefit from 
an increase in rectal motility induced by suppositories,55 while pa-
tients	with	reduced	number	of	HAPCs	might	benefit	more	from	an	
oral formulation with a more combined effect on secretion and mo-
tility. However, in the absence of ad hoc studies, it is difficult to as-
certain whether a specific subgroup of constipation patients would 
benefit more from oral or local administration.
Recent observations on the different effects on colon motility of 
some of the currently available constipation treatments (bisacodyl, 
PEG, and prucalopride) may provide useful information for clinical 
practice.54 It is indeed possible that the use of a combination of dif-
ferent medications, which target different colonic motor patterns, 
could help patients currently not responding to monotherapy. It is 
also interesting to note that bisacodyl has been used as a rescue 
medication in many recent clinical trials designed to investigate 
the efficacy of newer compounds, such as linaclotide and prucalo-
pride.16,17,19,20 This is unsurprising considering that bisacodyl stim-
ulates	 HAPCs	 in	 healthy	 individuals,	 while	 prucalopride	 seems	 to	
stimulate low- amplitude simultaneous pressure increases and in-
crease	the	amplitude	of	HAPCs.
It is interesting to note that some in vitro studies suggest that in-
creasing the dose of bisacodyl above the recommended dosage may 
not increase the colon motor response.49 This could explain the fact 
that patients reporting consumption of very high dosages of bisaco-
dyl do not seem to experience stronger stimulation of colon motility.
6.4  |  Can bisacodyl be considered safe for long- 
term use?
The current evidence for the efficacy and safety of bisacodyl 
compared with placebo has been obtained over a period of up to 
4 weeks.21 However, clinical experience, guidelines, and review 
articles suggest that there are no concerns with using these laxa-
tives over a longer period of time.9,70- 72 In this case, use of these 
medications with a frequency of two to three times a week may 
be considered, as the aim should be to have at least two to three 
bowel movements per week according to the definition of normal 
bowel habits.6,73 However, some clinicians are still concerned about 
F I G U R E  5 Overview	of	mechanism	of	laxative	action	of	
bisacodyl and sodium picosulfate.
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the perception that prolonged use of stimulant laxatives can cause 
dependency or damage to the gut. It should be noted that these con-
cerns are based on historical anecdotal evidence and unwarranted 
fears. While some individuals are known to abuse laxatives,74 the ac-
tive metabolite from the stimulant laxatives bisacodyl and sodium pi-
cosulfate is not absorbed and does not pass through the blood- brain 
barrier and so there is no pharmacological basis for dependency. 
Furthermore, the misconception that long- term use of these laxa-
tives could damage the enteric nervous system is based on studies 
from 1960 to 1970, which have not been confirmed by subsequent 
studies.75- 79 Similarly, there are no concerns that these laxatives can 
increase the risk of colorectal cancer as a result of anthranoid de-
rivative associated colonic melanosis. This has been confirmed by 
prospective studies.75- 79	Available	evidence	does	not	 indicate	 that	
stimulant laxatives at recommended doses are harmful to the colon 
during long- term use.
7  |  CONCLUSIONS AND FUTURE 
PERSPEC TIVES
Bisacodyl is a prodrug with a unique dual mechanism of action on gut 
secretion and motility. The present analysis has reconfirmed that it is 
well tolerated and effective in the treatment of constipation, and the 
present review of the literature suggests that the treatment should 
be started with the lowest dose of 5 mg. Recent advances in the 
understanding of colonic motility in health and the distinct effects 
of available drugs for constipation on different colonic motor pat-
terns suggest that bisacodyl still has unexplored potential. Indeed, it 
would be interesting to understand whether the different response 
to the oral and rectal administration of the effect of bisacodyl could 
be used to improve the current treatment of patients presenting 
with impairment in proximal colon propulsion, compared with those 
with distal impairment. Furthermore, it would be interesting to in-
vestigate whether bisacodyl could be combined with other drugs, 
such as prucalopride, to treat patients not responding to monother-
apy. The results of studies in human samples clearly demonstrate 
that local administration of bisacodyl in vitro activates ion secretion 
both in the ileum and the colon, with an effect lasting between 20 
and 30 minutes.50 However, the relative role of secretion and motil-
ity in modulating the final laxative effect of bisacodyl in vivo when 
taken orally remains to be elucidated. Ongoing magnetic resonance 
imaging studies may clarify this relevant aspect.
Besides the well- known effect on initiating bowel movements, 
there are potentially further implications from the stimulation of 
large bowel motility with bisacodyl. Intestinal permeability and 
fecal flora have been assessed in patients with functional constipa-
tion to determine the impact of disturbances in bowel function.80 
Concentrations of Bifidobacterium and Lactobacillus were signifi-
cantly lower and potentially pathogenic bacteria and/or fungi were 
increased in constipated patients. Normalization of evacuatory 
function with bisacodyl treatment was accompanied by a decrease 
in counts of potentially pathogenic microorganisms (E. coli, fungi) 
and increase in counts of obligate microflora (Bifidobacterium, 
Bacteroides, Streptococcus fecalis).80 This is also an area that would 
warrant future research.
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